

FREND™ System

COVID-19 Neutralization Ab

Print Microfluidic Qualitative Immunoassay

Date/Time: 2013-9-24 2:11 PM
 User ID: NANO
 Patient ID: P-2

The **FREND™ COVID-19 Neutralization Ab** is a point-of-care testing (POCT) which can be used to check whether a patient has developed the immune response to SARS-CoV-2 using **human serum or plasma (EDTA)**. The FREND™ COVID-19 Neutralization Ab is a **fluorescence immunoassay (FIA)** using the FREND™ System intended for **the qualitative detection of neutralizing antibodies to SARS-CoV-2**. The FREND™ COVID-19 Neutralization Ab is intended for use as an aid in identifying individuals with neutralizing antibodies to SARS-CoV-2 after vaccination or prior infection.

Accurate




Easy



Monitoring




Steps



STEP 01.


Insert a cartridge into the AP device*.

*AP device is a fully automated pretreatment device.



STEP 02.


Add 35 μ L of sample to the dilution tube and mix well. Then, add 70 μ L of diluted sample to the pretreatment tube and insert the tube into the AP device.



STEP 03.

The cartridge loaded with 35 μ L of sample will be ejected after incubation. Then, insert the cartridge into the FREND™ System to get result.

Laboratory Information System Connectivity



In the event of a pandemic, the management of a vast amount of clinical results is important. As many laboratories face challenges in effective arrangement of the essential information⁽¹⁾, the **FREND™ System** provides the following advantages:

- Paperless
- Time-saving
- Automatic Data Transfer & Collection
- Convenient Data Management
- Can help monitoring (serosurveillance)

Reference

(1) Division of Laboratory Systems (DLS), Clinical Laboratory COVID-19 Response Call

Clinical Performance Evaluation

A total of 41 clinical samples (28 positive and 13 negative) confirmed with PRNT₅₀ were tested with the FREND™ COVID-19 Neutralization Ab, demonstrating 92.9% PPA* and 100% NPA* as shown below.



Method		PRNT ₅₀ confirmed	
		Positive	Negative
FREND™ COVID-19 Neutralization Ab	Reactive (Positive)	26	0
	Non-reactive (Negative)	2	13
Total		28	13

*Positive Percent Agreement (PPA), Negative Percent Agreement (NPA)

Specification

Item	Specification
Assay principle	Fluorescence immunoassay
Specimen	Serum or Plasma (EDTA)
Sample volume	35 µL
Reaction time	Cartridge reaction: < 3 minutes
Quantity	20 tests/kit
Storage condition	2 ~8 °C (35 ~46 °F)



Ordering Information

Product	Cat. No.
FREND™ System	F10
FREND™ COVID-19 Neutralization Ab	FRCON 020

Related Products

Cat. No.	Product	Quantity (tests/kit)
EPCO19 100	COVID-19 RT-PCR Kit	100
FRCOG 020P	COVID-19 Ag	20
FRCGFL 020	COVID-19 Ag+FLU A&B	20
FRCOA 020	COVID-19 total Ab**	20
FRCOD 020	COVID-19 IgG/IgM Duo	20
FRCOS 020	COVID-19 SP	20

**FDA EUA Approved



NESCT-FRCON-001E (V.0.0)



Scan for more information.

NanoEntek, Inc.

Head Office

12F, 5, Digital-ro 26-gil, Guro-gu, Seoul, 08389, Korea
Tel: +82-2-6220-7940/Fax: +82-2-6220-7999

NanoEntek America, Inc.

Waltham, MA, USA Tel: +1-781-472-2558

NanoEntek Bio-Technology(Beijing) Ltd.

Fengtai District, Beijing Tel: +86-10-5920-7980

website www.nanoentek.com

e-mail ivdst@nanoentek.com